Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 80 Years; excludes diabetes; BMI ≥27 required; conditions: Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight
- Interventions
- Tirzepatide; Standard Care (in control arm)
- Conditions
- Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight
- Phase and size
- NA · 200 participants
- Dates
- Start 2026-06-16
Primary completion 2027-12-31 - Sponsor
- National Taiwan University Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Atrial fibrillation burden at 3 months after catheter ablation3 months after catheter ablation (7-day ECG patch monitoring period)
02Eligibility
Who can take part
Inclusion Criteria: 1. Age between 18 and 80 years. 2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation. 3. Body mass index (BMI) ≥27 kg/m² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes). 4. Able and willing to provide written informed consent. Exclusion Criteria: 1. Long-standing AF or marked left atrial enlargement (persistent AF duration \> 5 years or left atrial anterior-posterior diameter \> 50 mm). 2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery). 3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy). 4. Planned major non-AF-related surgery or interventional procedure within 3 months. 5. Other arrhythmias requiring chronic antiarrhythmic drug therapy. 6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator. 7. Active systemic infection at screening. 8. Contraindications to tirzepatide or GLP-1/GIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption). 9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant. 10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study. 11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period. 12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.
03Change log
Registry changes
No changes recorded since the trial was added.